ObjectivesTo systematically review the safety and efficacy of aspirin in primary prevention of cardiovascular diseases.MethodsPubMed, EMbase, Web of Science, The Cochrane Library, CBM, WanFang Data, CNKI and VIP databases were electronically searched to collect randomized controlled trials (RCTs) of aspirin for primary prevention of cardiovascular diseases from inception to November 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, and then, meta-analysis was performed by RevMan 5.3 software.ResultsA total of 13 RCTs involving 164 225 participants were included. The results of meta-analysis showed that: aspirin reduced the risk of myocardial infarction (RR=0.85, 95%CI 0.75 to 0.97, P=0.01), ischemic stroke (RR=0.86, 95%CI 0.79 to 0.95, P=0.002) and risk of major adverse cardiovascular events (RR=0.90, 95%CI 0.86 to 0.94, P<0.000 1). However, all-cause mortality (RR=0.97, 95%CI 0.93 to 1.02, P=0.22) and cardiovascular mortality (RR=0.93, 95%CI 0.85 to 1.02, P=0.11) were not reduced. Additionally, it increased risk of hemorrhagic stroke (RR=1.29, 95%CI 1.02 to 1.64, P=0.03), major bleeding (RR=1.43, 95%CI 1.31 to 1.56, P<0.000 01) and gastrointestinal bleeding (RR=1.59, 95%CI 1.33 to 1.90, P<0.000 01).ConclusionCurrent evidence shows that aspirin can reduce the incidence of major adverse cardiovascular events and myocardial infarction during primary prevention of cardiovascular disease, while increase the risk of bleeding, especially gastrointestinal bleeding. Therefore, its potential benefits may be offset. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusion.
ObjectiveTo investigate the correlation between lipid accumulation product (LAP) and risk of ischemic cardiovascular disease (ICVD).
MethodsThis cross-sectional study was performed among community residents from an urban community in Chengdu area between September 2011 and June 2012. Questionnaire survey was carried out. Each individual underwent biochemistry analysis and physical examination. In addition, brachial-ankle pulse wave velocity (BaPWV) and augmentation index (AI) were detected. Pearson correlation analysis was performed to explore the relationship between LAP and each cardiovascular risk factor. Liner regression model was used to analyze the relationship between LAP and ICVD.
ResultsA total of 780 individuals with complete data were included in the analysis. LAP was correlated with blood pressure, total cholesterol, high density lipoprotein cholesterol, fasting blood glucose, and BaPWV (P＜0.05). LAP was associated with the risk of ICVD (r=0.253, P＜0.001). After being adjusted with sex, age and other cardiovascular risk factors, LAP was also correlated with the risk of ICVD (r=0.050, P＜0.001).
ConclusionsHigh LAP is associated with elevated cardiovascular risks and subclinical vascular damage. In addition, LAP is correlated with ICVD risk, thus it may be used to predict the incidence of ICVD to some extent. However, as the correlation is weak, our study does not support the direct use of this indicator to predict ICVD. Large-sample studies based on different races and ages are needed.
Cardiovascular disease is the leading cause of death worldwide, accounting for 48.0% of all deaths in Europe and 34.3% in the United States. Studies have shown that arterial stiffness takes precedence over vascular structural changes and is therefore considered to be an independent predictor of many cardiovascular diseases. At the same time, the characteristics of Korotkoff signal is related to vascular compliance. The purpose of this study is to explore the feasibility of detecting vascular stiffness based on the characteristics of Korotkoff signal. First, the Korotkoff signals of normal and stiff vessels were collected and preprocessed. Then the scattering features of Korotkoff signal were extracted by wavelet scattering network. Next, the long short-term memory (LSTM) network was established as a classification model to classify the normal and stiff vessels according to the scattering features. Finally, the performance of the classification model was evaluated by some parameters, such as accuracy, sensitivity, and specificity. In this study, 97 cases of Korotkoff signal were collected, including 47 cases from normal vessels and 50 cases from stiff vessels, which were divided into training set and test set according to the ratio of 8 : 2. The accuracy, sensitivity and specificity of the final classification model was 86.4%, 92.3% and 77.8%, respectively. At present, non-invasive screening method for vascular stiffness is very limited. The results of this study show that the characteristics of Korotkoff signal are affected by vascular compliance, and it is feasible to use the characteristics of Korotkoff signal to detect vascular stiffness. This study might be providing a new idea for non-invasive detection of vascular stiffness.
Objective To observe and analysis the features of images of fundus fluorescein angriography (FFA) in low-perfused retinopathy caused by cephalo-cervical peripheral vascular stenosis or occlusion. Methods The results of FFA of 27 patients diagnosed with carotid artery stenosis or occlusion by digital subtraction angiography (DSA) and examination of Doppler and vascular-pulsation were retrospectively analyzed. Result All of the patients had a delayed arm-retinal circulation duration from 20.0 to 81.08 seconds with the mean of 32.1 seconds; a delayed retinal arteriovenous filling duration from 6 to 64.0 seconds with the mean of 24.2 seconds. Delayed arm-retinal circulation duration and retinal a rteriovenous filling duration in 10 cases (37.0%); microangioma, vascular wall staining, nonperfused capillary area in 11 (40.7%); and anterior ischemic syndrome in 6 (22.2%) were found. In the 6 patients with anterior ischemic syndrome, 4 cases had narrow retinal artery, segmental changes of blood stream, vascular atresia, and abnormal arterio-venous anastomosis, and 2 cases had bold vascular loops. Conclusions The main manifestations of FFA in patients with low-perfused retinopathy are malperfusion and retinal ischemia, whose degrees relate to the extend of carotid artery stenosis or atresia, and the process of the disease.Serious retinal ischemia may combined with anterior ischemic syndrome. (Chin J Ocul Fundus Dis，2004，20：84-86)
ObjectivesTo systematically review the efficacy of Nordic walking on prognosis of cardiovascular diseases. MethodsPubMed, Web of Science, EMbase, The Cochrane Library, CBM, CNKI and VIP databases were electronically searched to collect intervention studies on the efficacy of Nordic walking on prognosis of cardiovascular diseases from inception to June, 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by RevMan 5.3 software. ResultsA total of 9 studies involving 328 patients were included. The results of meta-analysis showed that: compared with control group, there were an obvious decrease in the values of LDL (MD=–11.38, 95%CI –17.51 to –5.25, P=0.000 3), TG (MD=–21.14, 95%CI –32.33 to–9.96, P=0.000 2), SBP (MD=–7.96, 95%CI ?11.45 to –4.46, P<0.000 01) and TC, DBP, BMI (P<0.05). However, there were no obvious differences between two groups in HDL. ConclusionsNordic walking can improve the prognosis of patients with cardiovascular diseases, yet the long-term effect is unclear. Due to limited quality and quantity of the included studies, more higher quality studies are required to verify above conclusions.
Sclerostin, as a bone-derived secreted glycoprotein, is a suppressor of Wnt signaling pathway. Recently, adverse cardiovascular events in the treatment of osteoporosis with sclerostin inhibitors have raised concerns about the association of sclerostin with atherosclerotic heart disease. Whether the role of sclerostin in atherosclerotic heart disease is harmful or beneficial is not clear. This article reviews the progress of the mechanisms of sclerostin in vascular calcification and atherosclerotic heart disease, focusing on the relationship between sclerostin and vascular calcification, the impact of its concentration changes on atherosclerotic heart disease, and the effect of sclerostin inhibitor on cardiovascular events.
With the prevalence of cardiovascular diseases, the development of cardiac rehabilitation is an inevitable trend. Cardiac rehabilitation is a comprehensive and long-term plan including medical assessment, exercise prescription, correction of cardiovascular risk factors, education, counseling, and behavioral intervention. Evidence-based medical evidence confirms that cardiac rehabilitation plays an important role in the three level prevention of cardiovascular disease. In this paper, we searched the literature in recent 10 years to explain the current situation and future research direction of cardiac rehabilitation, and explore the best mode of cardiac rehabilitation.
目的:探討氟西汀聯合心理干預治療心血管疾病患者伴焦慮抑郁癥狀的臨床療效。方法:選擇伴有抑郁、焦慮情緒障礙的85例冠心病患者(心功能Ⅱ、Ⅲ級),并將其隨機分成研究組和對照組。觀察6w,對照組患者僅給予常規的治療,研究組患者在常規治療基礎上給予氟西汀聯合心理干預治療。觀察治療前后兩組患者采用漢密頓焦慮量表( Hamilton Anxiety Scale,HAMA) 評定焦慮癥狀,漢密頓抑郁量表( Hamilton Depression Scale,HAMD) 評定抑郁癥狀;并對治療后心功能分級(NYHA)恢復到Ⅰ級的例數及左室射血分數進行分析評價。結果:治療6 周 后,研究組均較對照組的漢密頓焦慮量表及漢密頓抑郁量表評分下降顯著( P lt;0.01),研究組抗焦慮顯效率為87.16%、抗抑郁顯效率為82.26%,對照組分別為43.75%、45.36%,研究組均顯著高于對照組( P lt;0.01);研究組患者的左室射血分數顯著高于對照組 ( P lt;0.05),心功能分級(NYHA)恢復到Ⅰ級的例數顯著高于對照組 ( P lt;0.05)。結論:氟西汀聯合心理干預治療不僅能改善心血管疾病伴焦慮抑郁患者的焦慮、抑郁情緒障礙,還能改善患者的心功能,療效顯著優于單用心血管藥物治療。
